<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781753</url>
  </required_header>
  <id_info>
    <org_study_id>921601</org_study_id>
    <nct_id>NCT02781753</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin SinoBiotech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin SinoBiotech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dosages of recombinant human serum
      albumin/interferon alpha2b fusion protein injection in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study that will be conducted at a single site in China to characterize
      the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon
      alpha2b Fusion Protein in healthy subjects. Subjects will receive a single dose of
      Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator
      Pegasys at Day 0. The total duration of study participation is up to 6 weeks for each
      subject. Subjects will complete a follow-up visit at Day 28 after the dosing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events after single dose</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of interferon after single dose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Neopterin after single dose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Human Serum Albumin/interferon alpha2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon 180 μg single dose S.C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Serum Albumin/interferon alpha2b</intervention_name>
    <description>Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0</description>
    <arm_group_label>Human Serum Albumin/interferon alpha2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon 180 μg single dose S.C.</intervention_name>
    <description>Pegasys 180 mcg S.C. single dose on Day 0</description>
    <arm_group_label>Pegasys</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be healthy males or females between 18 to 45 years old, inclusive

          -  Must have a body mass index (BMI) of 19 to 25 kg/m2, inclusive, and a minimum body
             weight of 50.0 kg

        Exclusion Criteria:

          -  History of any clinically significant laboratory abnormalities, cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, or other major diseases

          -  Female subjects who are pregnant or breastfeeding

          -  Any previous treatment with Human Albumin Interferon fusion protein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meixia Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meixia Wang, Professor</last_name>
      <phone>+86-10-83997181</phone>
      <email>wangmeixiad@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 20, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
